ArticleEuropean journal of cancer (Oxford, England : 1990)2019
Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer.
Article in European journal of cancer (Oxford, England : 1990), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Prognostic Value of Tumor Infiltrating Lymphocytes in Nasopharyngeal Carcinoma Patients: Meta-Analysis.Technology in cancer research & treatmentPooled it
- Immune Phenotype in Urothelial Carcinoma: From Tumor Biology to Therapeutic Stratification.Cancers · 2026Review
- Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy.Clinical and translational medicine · 2026Article
- The role of tumor-infiltrating lymphocytes and depth of invasion in T1 bladder cancer: a retrospective analysis.BMC urology · 2025Article
- Immunohistochemical Evaluation of Basal and Luminal Markers in Bladder Cancer: A Study from a Single Institution.Life (Basel, Switzerland) · 2024Article
- Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer.Translational cancer research · 2024Review
- Review
- Immunochemistry-based quantification of tumor-infiltrating lymphocytes and immunoscore as prognostic biomarkers in bladder cancer.Journal of the Egyptian National Cancer Institute · 2024Article
- Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer.Cancer immunology, immunotherapy : CII · 2023Review
- Cancer Microenvironment Defines Tumor-Infiltrating Lymphocyte Density and Tertiary Lymphoid Structure Formation in Laryngeal Cancer.Head and neck pathology · 2023Article
- A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer.European journal of nuclear medicine and molecular imaging · 2022Article
- BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer.The Journal of clinical investigation · 2022Article
- Non-muscle invasive bladder cancer biomarkers beyond morphology.Frontiers in oncology · 2022Review
- A Robust Immuno-Prognostic Model of Non-Muscle-Invasive Bladder Cancer Indicates Dynamic Interaction in Tumor Immune Microenvironment Contributes to Cancer Progression.Frontiers in genetics · 2022Article
- Prognostic role of stromal tumor-infiltrating lymphocytes in locally advanced upper tract urothelial carcinoma: A retrospective multicenter study (TSU-02 study).Oncoimmunology · 2021Article
- STC1 is a Novel Biomarker Associated with Immune Characteristics and Prognosis of Bladder Cancer.International journal of general medicine · 2021Article
- Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer.The journal of pathology. Clinical research · 2020Article
- New Roadmaps for Non-muscle-invasive Bladder Cancer With Unfavorable Prognosis.Frontiers in chemistry · 2020Review
- Prognosis in high-grade T1 bladder cancer: host immune response and tumour infiltrating lymphocytes.Translational andrology and urology · 2019Article
- Comment on: Relationship between the expression of PD-1/PD-L1 andEuropean journal of nuclear medicine and molecular imaging · 2019Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAssessment of tumour-infiltrating lymphocytes (TILs) can provide important prognostic information in various cancers and may be of value in predicting response to immunotherapy. The objective of the present study was to investigate the association of stromal lymphocytic infiltration with clinicopathological parameters and their correlation with outcomes in patients with high-grade pT1 non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND
methodsWe retrospectively analysed clinical data and formalin-fixed paraffin-embedded (FFPE) tissues of 147 patients with primary high-grade pT1 NMIBC who underwent transurethral resection of the bladder. The stromal TIL density was scored as percentage of the stromal area infiltrated by mononuclear inflammatory cells over the total intratumoural stromal area. The main end-point was correlation with cancer-specific survival (CSS).
resultsMedian follow-up was 8.2 years (6.1-9.5). Induction Bacillus Calmette-Guérin therapy was undergone by 126 patients (86%). Stromal TILs were high (≥10%) in 82 tumours (56%) and were positively associated with the tumour invasion depth (p = 0.01) and cancers with variant histology (p = 0.01). For the CSS analysis, high (≥10%) versus. low (<10%) stromal TIL hazard ratio (95% confidence interval) was 1.70 (0.7-3.9, p = 0.2).
conclusionsA higher density of stromal TILs was associated with the tumour invasion depth in pT1 NMIBC. The level of TILs was not associated with survival outcomes. These data suggest that tumour aggressiveness is associated with an increased adaptive immune response in pT1 NMIBC. Characterisation of T-cell subtypes along with B-cells may be critical to enhance our knowledge of the host immune response in patients with high-risk NMIBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.